Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 5.87M P/E - EPS this Y 62.70% Ern Qtrly Grth -
Income -4.7M Forward P/E -4.45 EPS next Y 34.70% 50D Avg Chg 12.00%
Sales 2.52M PEG - EPS past 5Y - 200D Avg Chg -8.00%
Dividend N/A Price/Book 0.46 EPS next 5Y - 52W High Chg -61.00%
Recommedations 3.00 Quick Ratio 4.60 Shares Outstanding 1.54M 52W Low Chg 61.00%
Insider Own 19.03% ROA -28.74% Shares Float 1.18M Beta 2.26
Inst Own 0.97% ROE -48.61% Shares Shorted/Prior 5.96K/19.43K Price 3.87
Gross Margin 100.00% Profit Margin -186.33% Avg. Volume 34,535 Target Price -
Oper. Margin -184.11% Earnings Date Nov 7 Volume 1,113 Change 0.02%
About Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments that targets pancreatic cancer comprising pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase enzyme for use in treatment of cancer; and exclusive license agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase in conjunction with CAR T therapies. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Xenetic Biosciences, Inc. News
11/21/24 Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
11/15/24 Xenetic Biosciences Third Quarter 2024 Earnings: Misses Expectations
11/13/24 Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
11/12/24 Xenetic Biosciences: Q3 Earnings Snapshot
11/12/24 Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models
11/07/24 Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
07:45 AM Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
10/17/24 Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform
09/11/24 Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference
08/14/24 Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
08/13/24 Xenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue Estimates
08/13/24 Xenetic Biosciences: Q2 Earnings Snapshot
04:00 PM Xenetic Biosciences, Inc. Announces Executive Leadership Transition
05/12/24 Xenetic Biosciences First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
05/10/24 Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
05/09/24 Xenetic Biosciences (XBIO) Reports Q1 Loss, Misses Revenue Estimates
03/24/24 Xenetic Biosciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
07:00 AM Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results
01/17/24 Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
11/30/23 Most Shareholders Will Probably Agree With Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation
XBIO Chatroom

User Image Waldo_III Posted - 6 days ago

@GenerallyGentle Looks like $XBIO is having a good year up over 30%. $OTLK that’s a while other story? Down over 40% so far for the year. Losing 80% from FDA rejection has been a total nightmare for investors! Ship has sunk with a life raft that has serious holes..

User Image jimsmits Posted - 1 week ago

$XBIO market loves this No doubt it will be ramped at some stage to raise more money to pay the directors

User Image Maya_Ah Posted - 1 week ago

💥 Boom 🚨 $SBFM $XBIO — let’s crush these short sellers. This is massive news: MYNZ (mkt cap $7M) teaming up with TMO (mkt cap $209B). You don’t often see a collab like this! Another big PR is definitely on the way, and this is set to take off. Place your order all at once at 1 PM NY time, make a splash, and push the short sellers out.

User Image jimsmits Posted - 1 week ago

$XBIO no one care about this Data presented at Society for Immunotherapy of Cancer (SITC) 2024 Systemic DNase I combined with 𝛼-CTLA-4 antibody demonstrated to promote antitumor immunity and generate immunological memory against microsatellite stable, mismatch repair proficient colorectal carcinoma (CRC) tumors

User Image NylahShep_ Posted - 1 week ago

MYNZ 🔥 Perfect time to jump in, cheapest dip!!! Shorts volume increased. HUGE PR drop incoming before the Nov 13 meeting, so compliance is coming, no RS needed. Here is why… 1.Frankie Muniz backing Mainz (yes, the Malcolm guy & NASCAR #33 now repping MYNZ). 2.Petra, ex-Obama advisor, hinted at a big U.S. lab partner. Solid source! 3.Six news hits in 3 weeks—momentum. 4.Already solid in the EU, not new but expanding, with insurance covering their tests. 5.Their test has 88% accuracy vs. EXAS (42%) & GH (20%)—big edge! 6.$1.5M private placement in the bag. 7.CEO teased big plans ahead. 8.Offering Deal $XBIO $BFRI

User Image HeatherW80 Posted - 2 weeks ago

$ENSC Is moving on up! $xbio $SNTI $TLIS

User Image jimsmits Posted - 10/31/24

$XBIO Takeda earnings are up and projected to be 18% up next year Hopefully some of this comes XBIO way with their drug

User Image jimsmits Posted - 10/30/24

$XBIO something is up

User Image jimsmits Posted - 4 weeks ago

$XBIO zzzzzzzzzzzzzzz

User Image GreedyBastard4Ever Posted - 4 weeks ago

$XBIO Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

User Image DonCorleone77 Posted - 1 month ago

$XBIO Xenetic files $50M mixed securities shelf The company may offer, issue and sell, from time to time, shares of its common stock, preferred stock, warrants, units, rights, depositary shares and debt securities which may consist of debentures, notes, or other types of debt, in one or more offerings with an aggregate offering price not to exceed $50M.

User Image jimsmits Posted - 1 month ago

$XBIO no one cares

User Image GreedyBastard4Ever Posted - 1 month ago

$XBIO Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform

User Image snapbuy Posted - 1 month ago

$XBIO will head for 6.00 in no time by thursday

User Image St0ckt0k101 Posted - 09/30/24

$XBIO 🤔😬💯🎯

User Image VrtcIl Posted - 09/30/24

$XBIO is currently achieving new intraday highs, showing a bullish momentum on the technical charts. How far can this thing run guys? Price: 5.02 Float: 1.2M Short Float: 0.4 % 💰 Dollar Volume: 1.9K ℹ️ USA | Biotechnology

User Image bizzy99 Posted - 09/30/24

$XBIO

User Image VrtcIl Posted - 09/30/24

How much more potential do you see on $XBIO? 5? 7? 10? Look for key indicators such as trend strength, support and resistance levels, and potential breakout or reversal patterns. Price: 4.57 Float: 1.2M Short Float: 0.4 % 💰 Dollar Volume: 4.5K ℹ️ USA | Biotechnology

User Image Stock_Titan Posted - 2 months ago

$XBIO Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference https://www.stocktitan.net/news/XBIO/xenetic-biosciences-inc-presents-at-the-h-c-wainwright-26th-annual-9x2cpbpw817d.html

User Image intratio Posted - 2 months ago

$XBIO https://www.intratio.com/stock-forecast/XBIO Xenetic Biosciences, Inc. The mathematical model reaches the conclusion the stock price of this company will have a short-term downward trend and will be trending downward in the following months

User Image Article_AI Posted - 3 months ago

$XBIO H.C. Wainwright Sticks to Their Hold Rating for Xenetic Biosciences (XBIO) In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Hold rating on Xenetic Biosciences (XBIO – Research Report). The com... https://www.stck.pro/news/XBIO/87440414/

User Image intratio Posted - 3 months ago

$XBIO https://www.intratio.com/stock-forecast/XBIO The statistical model concludes that this company s value has a good prognosis for the near future and has no clear long-term directional perspective

User Image intratio Posted - 3 months ago

$XBIO https://www.intratio.com/stock-forecast/XBIO The network is making the inference that the price action of this stock has a nice setup for the immediate future and the stock price is consistent with the company s long-term fundamentals

User Image kinderspiel Posted - 3 months ago

Aug 15 volume of shares traded $MNKD 773.3 k $TTOO 62.8 k $XBIO 51.6 k $MBRX 31.1 k $ALZN 12.2 k

User Image jParkz Posted - 3 months ago

News $XBIO Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update https://marketwirenews.com/news-releases/xenetic-biosciences-inc-reports-second-quarter-2024--5298662145716313.html $XBIO

User Image jimsmits Posted - 3 months ago

$XBIO spending is down Not really sure what this company does anymore apart from pay staff to file accounts

User Image HaltTradeAlert Posted - 3 months ago

$XBIO Halt Time: 09:30:28 Issue Symbol: XBIO Reason Code: LUDP Last Price: $3.01 Volume: 2.3 K Members get this halt alert with no delay and with more info: shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!

User Image Stock_Titan Posted - 3 months ago

$XBIO Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update https://www.stocktitan.net/news/XBIO/xenetic-biosciences-inc-reports-second-quarter-2024-financial-74d5sn8roenx.html

User Image profmario Posted - 3 months ago

$XBIO 2022 -> 2024

User Image jimsmits Posted - 3 months ago

$XBIO removal of warrants Clowns

Analyst Ratings
HC Wainwright & Co. Neutral Aug 20, 24
HC Wainwright & Co. Neutral May 16, 23